151 related articles for article (PubMed ID: 33171596)
1. Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis.
Wu CE; Yeh DW; Pan YR; Huang WK; Chen MH; Chang JW; Chen JS; Wang YC; Yeh CN
Life (Basel); 2020 Nov; 10(11):. PubMed ID: 33171596
[TBL] [Abstract][Full Text] [Related]
2. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
4. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.
Yang H; Gou X; Feng C; Zhang Y; Chai F; Hong N; Ye Y; Wang Y; Gao B; Cheng J
J Transl Med; 2023 Jan; 21(1):4. PubMed ID: 36604653
[TBL] [Abstract][Full Text] [Related]
5. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
[TBL] [Abstract][Full Text] [Related]
6. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
Rizzo A; Ricci AD; Brandi G
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
8. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors.
Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
Ther Adv Med Oncol; 2021; 13():1758835921992992. PubMed ID: 33717226
[TBL] [Abstract][Full Text] [Related]
9. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
[TBL] [Abstract][Full Text] [Related]
10. Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort.
Li C; Ding Y; Zhang X; Hua K
Discov Oncol; 2022 Jul; 13(1):65. PubMed ID: 35834061
[TBL] [Abstract][Full Text] [Related]
11. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
12. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
Eso Y; Seno H
Therap Adv Gastroenterol; 2020; 13():1756284820948773. PubMed ID: 32913444
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal instability as a prognostic marker in cervical cancer.
How C; Bruce J; So J; Pintilie M; Haibe-Kains B; Hui A; Clarke BA; Hedley DW; Hill RP; Milosevic M; Fyles A; Liu FF
BMC Cancer; 2015 May; 15():361. PubMed ID: 25944123
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer.
Huang J; Liu H; Zhao Y; Luo T; Liu J; Liu J; Pan X; Tang W
Front Oncol; 2020; 10():550986. PubMed ID: 33634010
[TBL] [Abstract][Full Text] [Related]
15. Association of ATRX mutations with immunologically active characteristics in patients with MSI-prone tumors.
Ge Y; Wang Z; Li H; Liu Y; Wei P
Am J Transl Res; 2022; 14(9):6107-6122. PubMed ID: 36247274
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.
Ang C; Klempner SJ; Ali SM; Madison R; Ross JS; Severson EA; Fabrizio D; Goodman A; Kurzrock R; Suh J; Millis SZ
Oncotarget; 2019 Jun; 10(40):4018-4025. PubMed ID: 31258846
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
Front Oncol; 2020; 10():1409. PubMed ID: 32974146
[TBL] [Abstract][Full Text] [Related]
18. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
19. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
20. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
